3-Month Home-based Training With Whole Body Vibration Device in Patients With PAH (GALILEO-PAH-HOME)

Changes in Six Minute Walking Distance, Peak Oxygen Uptake, Quality of Life Clinical Trial

— GALILEOHOME  

Official title:

Influence of Training With Whole Body Vibration Device on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH) in an Extended 3-month Home Based Training. Background and Rationale for the Proposal: Capacity and the Ability to Exercise, in Patients With PAH is Limited. Primary Scientific Question Addressed:Changes in Muscle Power, Changes in 6-Minute Walk Distance (6MWD) and Changes in QoL Are to be Evaluated.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02997683
• Other study ID #: 002
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2018
• Est. completion date: December 2019

Study information

• Verified date: April 2019
• Source: Klinikum der Universität Köln
• Contact: Felix Gerhardt, MD
• Phone: +4947889413
• Email: felix.gerhardt[@]uk-koeln.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In order to evaluate Long term effects of whole Body Vibration (wbv) in patients with PAH and CTEPH patients will get a training device to use at home for 3 months. Patients in the Intervention group will be introduced in the training program on the wbv-device in the study center 3-4 times and baseline Parameters will be collected before start of the home based training. Patients randomized into the placebo arm be introduced into the training program according to the interventional arm but not perfoming the exercises on the wbv-device but on the floor.

Description:

Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera

Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).

Introduction Week -1(-7d-d1): All subjects will receive introduction in their training

Month 1:

Day 1: From this day subjects are supposed to start their training accoridng to protocol

Day 2: Telephone Visit

Day 5: Telephone Visit

Day 7: Telephone Visit

Day 10: Telephone Visit

Day 13: Telephone Visit

Day 20: Telephone Visit

Day 27: Telephone Visit

Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training

Month 2:

Week 5, Day 34:

Week 6, Day 41:

Week 7, Day 48:

Week 8, Day 55:

Month 3:

Week 9, Day 62:

Week 10, Day 69:

Week 11, Day 76:

Week 12, Day 83: Final Visit

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2019
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Men and women age 18-90 years

• Signed informed consent

• Symptomatic PAH (idiopathic, hereditary or associated with systemic scleroderma)

• Persistend or inoperable CTEPH

• Invasively confirmed PAH

• 6MWT = 50 - 450 m

• Stable specific therapy for at least 6 weeks

• Ability to perform bike test

• Ability to perform wbv training

• NYHA/WHO-FC II-III

Exclusion Criteria:

any other PAH/PH than idiopathic, hereditary, associated with systemic scleroderma or CTEPH

• Rehabilitation or other training concept performed within 6 weeks before inclusion

• pregnancy

• acute thrombosis

• newly implanted Hip or Knee

• recent bone fracture

• Disability to confirm consent

• NYHA/WHO-FC IV

• 6MWD below 50 or above 450 m

Related Conditions & MeSH terms

• Changes in Six Minute Walking Distance, Peak Oxygen Uptake, Quality of Life

Intervention

Device:
• Body Vibration platform GALILEO
3 month home based training on whole Body Vibration platform GALILEO

Other:
• exercises at home on the floor
exercises at home on the floor

Locations

Country	Name	City	State
Germany	Spezialambulanz für pulmonale Hypertonie Uniklinik Köln	Köln	NRW

Sponsors (1)

Lead Sponsor	Collaborator
Klinikum der Universität Köln

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in 6 Minute Walking distance		3 months
Primary	Changes in 6 Minute Walking distance		4 weeks interm analysis
Secondary	Changes in Peak Oxygen uptake in cardiopulmonary exercise testing (CPET)		3 months
Secondary	Changes in Peak Oxygen uptake in cardiopulmonary exercise testing (CPET)		4 weeks
Secondary	Changes in Quality of Life		3 months
Secondary	Changes in Quality of Life		4 weeks